Clinical trial · Interventional
Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma
Continuous Access to Advanced and Metastatic Renal Cell Carcinoma Therapy With Everolimus Post Pazopanib Treatment
NCT01545817CI-TRIAL-00041057CATChEzterminatedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): As the therapeutic landscape in renal cell carcinoma is changing, it has become apparent that information gained so far by CATChEz study is sufficient.
Summary
Brief summary (as posted)
Study to determine the efficacy, safety and tolerability of first-line pazopanib followed by second-line everolimus in metastatic and advanced renal cell carcinoma. Due to changes in the RCC treatment landscape, info gained is no longer clinically relevant to patients. Data collected is deemed sufficient to meet objective.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Renal Cell | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pazopanib followed by everolimus | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Pazopanib followed by everolimus
- description
- First line pazopanib, followed by second line everolimus
- interventionNames
- Drug: Pazopanib followed by everolimus
Primary outcomes (1)
- measure
- Progression Free Survival (PFS) for the Everolimus Treatment Period Using RECIST
- timeFrame
- Throughout the study period, up to 4 years
- description
- Time between the date of first everolimus dose and date of disease progression or death (whichever comes first) in patients treated initially with pazopanib. Disease progression is measured by RECIST (Response Evaluation Criteria in Solid Tumors), which is at least a 20% increase in the sum of the target lesion longest diameters (LDs).
Secondary outcomes (6)
- measure
- Progression Free Survival (PFS) Rates
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: * Age \>=18 years * Histologically confirmed RCC with a clear-cell component * Locally advanced or metastatic RCC * At least one measurable lesion per RECIST 1.1 criteria, as determined by Computer Tomography (CT) Scan or Magnetic Resonance Imaging (MRI) * No systemic therapy for advanced or metastatic RCC prior to enrollment * Karnofsky Performance Status (KPS) ≥70 * Adequate baseline organ function * A female was eligible to enter and participate in this study if she was of: non-childbearing potential, or negative serum pregnancy test with agreement to use adequate contraception during the study * A male with female partner of childbearing potential must have vasectomy/agree to use effective contraception from 2 weeks prior to administration of the 1st dose of study treatment for a period of time after the last dose of study treatment * Able to swallow and retain orally administered medication and must not have clinically significant GI abnormalities that may alter absorption Additional inclusion criteria for starting everolimus: * Disease progression must be within 6 months after stopping pazopanib * At least one measurable lesion at the start of everolimus pe r RECIST 1.1 criteria, as determined by CT or MRI * In case of central nervous system (CNS) progression or metastasis during pazopanib treatment: asymptomatic or neurologically stable, no requirement of steroids to control CNS symptoms, and no requirement of enzyme-inducing anticonvulsants within 4 weeks prior to the start of everolimus Exclusion Criteria: * Lactating female * History of another malignancy (exception: patients disease-free for ≥3 years and patients with completely resected non-melanoma skin cancer or successfully treated in situ carcinoma) * Symptomatic CNS metastases at baseline * Clinically significant gastrointestinal abnormalities * Moderate to severe hepatic impairment (Child Pugh Class C) * Receiving chronic treatment with corticosteroids/other immunosuppressive agents * Active bleeding, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumadin) * Corrected QT interval (QTc) \>480 msec using Bazett's formula * Presence of any severe or uncontrolled medical conditions/infection * Poorly controlled hypertension (defined as systolic blood pressure of \>=140mmHg or diastolic blood pressure of \>=90mmHg) * History of cardiovascular disorders within the last 12 months (e.g. myocardial infraction or unstable angina), history of cerebrovascular events or pulmonary embolism within the last 6 months * Active bleeding or bleeding susceptibility * Known endobronchial lesion and/or lesions infiltrating major pulmonary vessels that increased the risk of pulmonary hemorrhage Additional criteria for exclusion from the second-line everolimus treatment period: \- The subject felt by the investigator to be unsuitable (on the basis of health, compliance, or for any other reason) for inclusion in the study.
References
Publications (0)
Data not yet available
No reference posted for this study.